Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia

Lu-Hong Xu1,2, Jian-Pei Fang1, Yao-Chung Li2,3, Adrianna I. Jones4,5 and Li Chai2

Abstract
Studies on the clinical significance of Nucleophosmin (NPM1) mutations in pediatric AML in a large cohort are lacking. Moreover, the prognosis of patients with co-occurring NPM1 and FLT3/ITD mutations is controversial. Here, we analyzed the impact of NPM1 mutations on prognoses of 869 pediatric AML patients from the TAGET dataset. The frequency of NPM1 mutations was 7.6%. NPM1 mutations were significantly associated with older age (P < 0.001), normal cytogenetics (P < 0.001), FLT3/ITD mutations (P < 0.001), and high complete remission induction rates (P < 0.05). Overall, NPM1-mutated patients had a significantly better 5-year EFS (P = 0.001) and OS (P = 0.016) compared to NPM1 wild-type patients, and this favorable impact was maintained even in the presence of FLT3/ITD mutations. Stem cell transplantation had no significant effect on the survival of patients with both NPM1 and FLT3/ITD mutations. Multivariate analysis revealed that NPM1 mutations were independent predictors of better outcome in terms of EFS (P = 0.004) and OS (P = 0.012). Our findings showed that NPM1 mutations confer an independent favorable prognostic impact in pediatric AML despite of FLT3/ITD mutations. In addition, pediatric AML patients with both NPM1 and FLT3/ITD mutations appear to have favorable prognoses and may not need hematopoietic stem cell transplantations.

Introduction
Acute myeloid leukemia (AML) is a genetically heterogeneous disease that accounts for about 20% of pediatric leukemia. The overall 5-year survival rate for pediatric patients with AML has increased over time and is now in the range of 65–70%1. Most of the advances have been made by better risk classification, the implementation of excellent supportive care measures, and improvements in allogeneic hematopoietic stem cell transplantation2. However, survival rates still vary depending on the subtype of AML and genetic risk factors. In recent years, molecular analysis has identified novel markers with prognostic relevance.

Nucleophosmin (NPM1) is a widely expressed protein predominantly located in the nucleolus that continuously shuttles between nucleus and cytoplasm. NPM1 performs diverse biological functions including molecular chaperoning, ribosome biogenesis, DNA repair, and maintaining genomic stability3. The human NPM1 gene is located on chromosome 5q35 and contains 12 exons. NPM1 mutations cause delocalization of the protein to the cytoplasm and are involved in leukemogenesis4,5. The WHO classification of hematopoietic malignancies recognizes AML with mutated NPM1 as a distinct entity6. Intriguingly, about 40% of NPM1-mutated AML cases have co-occurring FMS-like tyrosine kinase internal tandem duplication (FLT3/ITD) mutations7. However, the prognosis of patients with NPM1 co-occurring FLT3/ITD mutations is controversial. Numerous adult studies have shown that NPM1-mutated patients had improved
responses to treatment, only in the absence of FLT3/ITD mutations. Clinical data on pediatric AML patients with NPM1 mutations is lacking. A study of 295 childhood AML patients revealed that NPM1 mutations do not abrogate the negative prognostic influence of FLT3/ITD mutations. However, another cohort of 298 childhood AML study showed that NPM1 mutations confer a favorable prognosis in childhood, cytogenetically normal AML regardless of FLT3/ITD mutations. Hence, it is necessary to investigate the clinical significance of NPM1 mutations in pediatric AML in a large cohort.

Here, we analyzed the prevalence of NPM1 mutations in 869 pediatric AML patients from the therapeutically applicable research to generate effective treatment (TARGET) dataset. In addition, we evaluated the impact of these mutations on the patients’ prognoses and clinical profiles. Our findings showed that NPM1 mutations confer an independent favorable prognostic impact in the pediatric AML patients in spite of FLT3/ITD mutations. Moreover, pediatric AML patients with both NPM1 and FLT3/ITD mutations had favorable prognoses and may not require hematopoietic stem cell transplantations.

Materials and methods
Clinical data on pediatric patients with AML

Complete clinical data for 869 pediatric AML patients younger than 18 years old was downloaded from the TARGET dataset (April 2, 2019) (https://ocg.cancer.gov/programs/target/data-matrix). According to the dataset, year of diagnosis ranged from 1996 to 2010. Year of last follow-up ranged from 1997 to 2015. Diagnosis and subtype classifications of AML were assigned according to the French–American–British (FAB) classifications. Treatment protocols for AML included AAML03P1, AAML0531 and CCG-2961, all of which consisted of a remission induction phase followed by an intensification phase. Stem cell transplantation (SCT) was considered for patients in the first complete remission. Written informed consent was obtained from all study participants. Informed consent was obtained in accordance with the Declaration of Helsinki. Cytogenetic analyses in situ were performed by standard G-banding/fluorescence in situ hybridization techniques. Molecular analyses for FLT3/ITD and NPM1 mutations were performed on genomic DNA by polymerase chain reaction (PCR).

Statistical analysis

Chi-squared analysis and Fisher’s exact test, in cases of small numbers, were used to compare categorical variables. The nonparametric Mann–Whitney U-test was applied for continuous variables. To assess outcome, the following parameters were used: complete remission (CR, defined as a normocellular BM containing fewer than 5% blasts) rate, event-free survival (EFS, defined as time between diagnosis and first event, including induction failure, relapse or death of any cause), overall survival (OS, defined as time between diagnosis and death from any cause). EFS and OS were estimated by the Kaplan–Meier method and compared using the log-rank test. Prognostic factors were examined by multivariate Cox regression analysis. P-values of <0.05 were considered statistically significant (two-tailed testing). The data were analyzed with the Statistical Package for the Social Sciences (SPSS®) version, 24.0 (IBM Corporation, Armonk, NY, USA).

Results

Relationship between NPM1 mutations and clinical characteristics

The characteristics of the study population, according to NPM1 mutation status, are shown in Table 1. Totally, among the 869 pediatric patients with AML, 66 patients (7.6%) were identified with NPM1 mutations. The median age in NPM1 mutations group and NPM1 wild-type group were 13.4 and 9.1, respectively, and the differences were statistically significant (P < 0.001). Moreover, the frequency was increasing along with the age in NPM1 mutations group: 4.5% below the age of 3 years; 22.7% in the age group 3 years or older but below 10 years, and 72.7% in children aged 10 years or older.

The distribution of FAB subtypes in NPM1 mutations group were mainly in M1, M2, M4, and M5 subgroups. Compared with the NPM1 wild-type group, the percentage of M1 subgroup was higher in NPM1 mutations group (26.8% vs 12.3%, P = 0.002). The treatment protocols for pediatric AML were equally distributed between these two groups (P = 0.915). Notably, NPM1 mutations were significantly associated with FLT3/ITD mutations (P < 0.001), normal cytogenetics (P < 0.001), transplantation status (P = 0.001). However, no significant difference was found in the median of FLT3/ITD allelic ratio between NPM1 mutations group and NPM1 wild-type group (P = 0.551).

Prognostic impact of NPM1 and FLT3/ITD mutations in pediatric AML

The CR rate was determined for the pediatric patients with AML. At the end of the first course of therapy, 57 (87.7%) of the 65 patients with NPM1 mutations achieved a CR compared with 598 (75.3%) of 794 patients without NPM mutations (P = 0.024). At the end of the second course of therapy, 63 (96.9%) of the 65 patients with NPM1 mutations achieved a CR compared with 672 (86.4%) of 778 patients without NPM mutations (P = 0.015). Thus, NPM1 mutations were significantly associated with high induction CR rates.

We then evaluated the survival data for all the 869 pediatric patients. The median follow-up time for all the
|                  | All patients | NPM1-mutated case | NPM1 wild-type case | P-value |
|------------------|--------------|-------------------|---------------------|---------|
| Number (%)       | 869          | 66 (7.6%)         | 803 (92.4%)         |         |
| Age, median (year)| 9.6          | 13.4              | 9.1                 | <0.001  |
| <3 years, n (%)  | 211 (24.3%)  | 3 (4.5%)          | 208 (25.9%)         | <0.001  |
| 3 ≤ Age <10 years, n (%) | 237 (27.3%) | 15 (22.2%)       | 222 (27.6%)         | 0.388   |
| 10 ≤ Age <18 years, n (%) | 421 (48.4%) | 48 (72.7%)       | 373 (46.5%)         | <0.001  |
| Sex (% female)   | 47.6%        | 50%               | 47.4%               | 0.690   |
| WBC, × 10^9/L, Median (range) | 31.7 (0.2-610) | 28.6 (2.1-360.5) | 32.1 (0.2-610) | 0.541   |
| FAB classification: N (%) |  |  |  | 0.151   |
| M0               | 20 (2.8%)    | 0 (0%)            | 20 (3.0%)           | 0.393   |
| M1               | 96 (13.5%)   | 15 (26.8%)        | 81 (12.3%)          | 0.002   |
| M2               | 193 (27.1%)  | 13 (23.2%)        | 180 (27.4%)         | 0.499   |
| M3               | 2 (0.3%)     | 1 (1.8%)          | 1 (0.2%)            | 0.151   |
| M4               | 192 (26.9%)  | 11 (19.6%)        | 181 (27.5%)         | 0.200   |
| M5               | 160 (22.4%)  | 16 (28.6%)        | 144 (21.9%)         | 0.252   |
| M6               | 11 (1.5%)    | 0 (0%)            | 11 (1.7%)           | >0.999  |
| M7               | 39 (5.5%)    | 0 (0%)            | 39 (5.9%)           | 0.064   |
| FLT3/ITD         |  |  |  | <0.001  |
| Positive, n (%)  | 146 (16.8%)  | 24 (36.4%)        | 122 (15.2%)         |         |
| Negative, n (%)  | 722 (83.2%)  | 42 (63.6%)        | 680 (84.8%)         |         |
| FLT3/ITD allelic ratio |  |  |  | 0.551   |
| Median (range)   | 0.54 (0.03-9.50) | 0.48 (0.03-9.50) | 0.55 (0.03-5.19) |         |
| Cytogenetic status |  |  |  | <0.001  |
| Normal (n, %)    | 196 (23.7%)  | 51 (81.0%)        | 145 (19.0%)         |         |
| Abnormal (n, %)  | 631 (76.3%)  | 12 (19.0%)        | 619 (81.0%)         |         |
| SCT in 1st CR    |  |  |  | 0.001   |
| No (n, %)        | 661 (83.7%)  | 45 (69.2%)        | 616 (85.0%)         |         |
| Yes (n, %)       | 129 (16.3%)  | 20 (30.8%)        | 109 (15.0%)         |         |
| Protocol         |  |  |  | 0.915   |
| AAML03P1 (n, %)  | 91 (10.5%)   | 6 (9.1%)          | 85 (10.6%)          | 0.703   |
| AAML0531 (n, %)  | 732 (84.2%)  | 56 (84.8%)        | 676 (84.2%)         | 0.887   |
| CCG-2961 (n, %)  | 46 (5.3%)    | 4 (6.1%)          | 42 (5.2%)           | 0.772   |
| CR status at end of course 1 |  |  |  | 0.022   |
| CR               | 655 (76.3%)  | 57 (87.7%)        | 598 (75.3%)         | 0.024   |
| Not CR           | 189 (22.0%)  | 8 (12.3%)         | 181 (22.8%)         | 0.050   |
| Death            | 15 (1.7%)    | 0 (0%)            | 15 (1.9%)           | 0.620   |
| CR status at end of course 2 |  |  |  | 0.014   |
| CR               | 735 (87.2%)  | 63 (96.9%)        | 672 (86.4%)         | 0.015   |
| Not CR           | 88 (10.4%)   | 2 (3.1%)          | 86 (11.1%)          | 0.043   |
| Death            | 20 (2.4%)    | 0 (0%)            | 20 (2.6%)           | 0.392   |

CR complete remission, FAB French–American–British morphology classification, FLT3/ITD internal tandem duplication of the FLT3 gene, SCT stem cell transplantation, WBC white blood cell count
survivors was 5.6 years. As shown in Fig. 1a, NPM1-mutated patients had a significantly better 5-year EFS (66.4 ± 6.0%) compared to wild-type patients (45.5 ± 1.8%; \( P = 0.001 \)). Moreover, NPM1-mutated patients had a significantly better 5-year OS (76.7 ± 5.6%) compared with wild-type patients (61.6 ± 1.8%; \( P = 0.016 \)) (Fig. 1b).

Survival data were also examined for the 868 patients for whom the FLT3/ITD mutation status was known (Fig. S1a, b). The presence of a FLT3/ITD mutation was significantly associated with inferior EFS (5-year EFS = 33.7 ± 4.0% vs 49.7 ± 1.9% for FLT3/ITD-negative; \( P < 0.001 \)) and OS (5-year EFS = 51.9 ± 4.3% vs 64.9 ± 1.8% for FLT3/ITD-negative; \( P = 0.004 \)). Next, we further investigated the effect of FLT3/ITD allelic ratio (AR) on survival using an AR threshold of 0.4 (Fig. S1c, d). However, we found that FLT3/ITD AR yielded no significant differences in 5-year EFS (30.9 ± 4.8% vs 38.5 ± 7.1%; \( P = 0.097 \)) and OS (50.5 ± 5.3% vs 54.1 ± 7.3%; \( P = 0.567 \)) between pediatric patients with high AR (>0.4, \( n = 95 \)) and low AR (≤0.4, \( n = 51 \)).

Since there is a significant association between NPM1 and FLT3/ITD status, subgroup analysis was performed to assess the relative contributions of NPM1 and FLT3/ITD to patient prognosis (Fig. 1c, d; Table 2). FLT3/ITD was a significantly poor prognostic factor for the NPM1 wild-type AML patients. However, we did not find that FLT3/ITD mutations, in combination with NPM1 mutations, had a negative influence on patient outcome (EFS hazard ratio: 1.050 (0.435–2.534), \( P = 0.914 \); OS hazard ratio: 1.283 (0.445–3.698), \( P = 0.645 \)). Notably, when restricted
to the FLT3/ITD-positive subgroup, NPM1-mutated patients had improved EFS (5-year EFS = 64.7 ± 10.2% vs 27.8 ± 4.1% for NPM1 wild-type patients; hazard ratio: 0.323 [0.156–0.667], P = 0.002) and OS (5-year OS = 72.8 ± 9.6% vs 47.8 ± 4.7% for NPM1 wild-type patients; hazard ratio: 0.408 [0.176–0.944], P = 0.022).

Prognostic impact of NPM1 mutations in the subgroup of cytogenetically normal AML

Overall, 196 pediatric patients were restricted to the subgroup of cytogenetically normal AML. As shown in Fig. 2a, b, NPM1 mutations conferred a favorable impact in prognosis in the subgroup of cytogenetically normal AML. The 5-year EFS for NPM1-mutated patients (n = 51) and NPM1 wild-type patients (n = 145) were 76.8 ± 6.2% and 37.4 ± 4.1%, respectively, and the difference was statistically significant (P < 0.001). In addition, the 5-year OS for these two groups were 84.1 ± 5.7% and 55.0 ± 4.2%, respectively (P = 0.001).

The data for combined NPM1 and FLT3/ITD status in the subgroup of cytogenetically normal AML are shown in Fig. 2c, d. Notably, there were no survival differences between NPM1-mutated-FLT3/ITD-positive (n = 18) and NPM1-mutated-FLT3/ITD-negative patients (n = 33), in terms of 5-year EFS (76.4 ± 10.4% vs 77.4 ± 7.5%; P = 0.985) and OS (87.7 ± 8.2% vs 81.9 ± 7.7%; P = 0.585).

Prognostic impact of NPM1 and SCT in pediatric AML

The percentage of SCT in NPM1 mutations group was higher than that in NPM1 wild-type group (30.8% vs 15.0%, P = 0.001). The survival analysis, after SCT stratification, of 790 NPM1-mutated pediatric AML patients is shown in Fig. 3. When restricted to no SCT, NPM1 mutations conferred a favorable prognostic impact on 5-year EFS (69.2 ± 7.1% vs 47.4 ± 2.0%; P = 0.006) and a trend of better 5-year OS (77.8 ± 6.6% vs 64.6 ± 2.0%; P = 0.07). However, when restricted to SCT, there was no significant difference between the NPM1-mutated group and the NPM1 wild-type group in terms of 5-year EFS (P = 0.751) and OS (P = 0.399).

In addition, to evaluate the role of SCT in AML patients according to FLT3/ITD status, we excluded 34 cases of AML patients with induction failure or death without CR in the analyses. As shown in Fig.S2 and Table S1, SCT appeared to improve 5-year EFS for patients with FLT3/ITD-negative (65.4 ± 5.4% vs 53.4 ± 2.1% for patients without SCT; hazard ratio: 0.672 [0.455–0.993], P = 0.046) or FLT3/ITD-positive (50.7 ± 7.2% vs 33.4 ± 6.0% for patients without SCT; hazard ratio: 0.628 [0.380–1.040], P = 0.070), but the differences were not statistically significant in FLT3/ITD-positive group. To further evaluate the role of SCT in patients with NPM1 co-occurring FLT3/ITD mutations, we excluded seven cases of FLT3/ITD-positive patients with induction failure or death without CR in the analyses. As shown in Fig. 4a, b, SCT improved the survival of patients with NPM1 wild-type and FLT3/ITD mutations in term of 5-year EFS (50.0 ± 8.6% vs 25.7 ± 5.9% for patients without SCT, P = 0.015), which did not translate into a significantly better 5-year OS (57.7 ± 8.7% vs 50.9 ± 6.8% for patients without SCT, P = 0.359). However, SCT had no significant effect on the survival of patients with both NPM1 and FLT3/ITD mutations, in term of 5-year EFS (51.4 ± 13.4% vs 85.7 ± 13.2% for patients without SCT, P = 0.086) or OS (56.2 ± 12.7% vs 85.7 ± 13.2% for patients without SCT, P = 0.257) (Fig. 4c, d).

Multivariate analysis of prognostic factors

When we included NPM1 mutations with other risk factors in the Cox model, including age (utilizing 10 years of age as the cutoff value), abnormal cytogenetics, FLT3/ITD and SCT as co-variables, we identified NPM1 mutations as an independent factor for both EFS and OS in pediatric patients with AML (Table 3). NPM1 mutations were significantly associated with better EFS (HR: 0.473, 95% CI: 0.283–0.790, P = 0.004) and OS (HR: 0.452, 95% CI: 0.242–0.841, P = 0.012). Moreover, SCT was significantly associated with better EFS (HR: 0.575, 95% CI: 0.419–0.790, P = 0.001), but not with better OS (HR: 0.824, 95% CI: 0.580–1.171, P = 0.280). On the contrary, FLT3/ITD mutations were significantly associated with worse EFS (HR: 1.743, 95% CI: 1.296–2.345, P < 0.001) and OS (HR: 1.600, 95% CI: 1.132–2.263, P = 0.008). In this model, the age and

Table 2 Statistical comparison of survival data according to both NPM1 and FLT3/ITD status in 868 pediatric AML.

| Comparison | EFS hazard ratio (95% CI) | EFS P-value | OS hazard ratio (95% CI) | OS P-value |
|------------|---------------------------|-------------|--------------------------|------------|
| FLT3/ITD(−): NPM1 wild-type vs NPM1 mutant | 0.524 (0.301–0.912) | 0.022 | 0.509 (0.251–1.029) | 0.060 |
| FLT3/ITD(+) NPM1 wild-type vs NPM1 mutant | 0.323 (0.156–0.667) | 0.002 | 0.408 (0.176–0.944) | 0.036 |
| NPM1 wild-type: FLT3/ITD(−) vs FLT3/ITD(+) | 1.763 (1.393–2.231) | <0.001 | 1.612 (1.218–2.132) | 0.001 |
| NPM1 mutant: FLT3/ITD(−) vs FLT3/ITD(+) | 1.050 (0.435–2.534) | 0.914 | 1.283 (0.445–3.698) | 0.645 |

CI confidence interval, EFS event-free survival, FLT3/ITD internal tandem duplication of the FLT3 gene, OS overall survival.
abnormal cytogenetics did not reach significance either for EFS or for OS.

**Discussion**

The TARGET program applies a comprehensive genomic approach to determine molecular changes that drive childhood cancers. The TARGET AML project team consists of multiple Children’s Oncology Group (COG) investigators at various institutions. The frequency of NPM1 mutations among 869 pediatric AML was 7.6%, which was lower compared with that of adult AML (range 25.4–41%). In agreement with other studies, NPM1 mutations have an increased incidence with increasing age. Three cases of NPM1 mutations were found in children below the age of 3 years in our study. However, no NPM1 mutations were found in children of this age group in other studies. Moreover, NPM1 mutations were predominately found in the FAB subtypes of M1, M2, M4, and M5. In other studies, however, the M5 subgroup harbored no NPM1 mutations. The differences might be due to our study including a large serial of pediatric patients. Our study confirmed that NPM1 mutations were significantly associated with FLT3/ITD mutations and normal cytogenetics. In addition, among the NPM1-mutated patients, 19% (12/63) of patients were identified with abnormal cytogenetics (Table S2). Only one NPM1-mutated patient was found either with the favorable karyotype t(8;21) or inv(16).
In agreement with adult studies, NPM1 mutations were significantly associated with high induction CR rates in our study. However, another pediatric study showed that NPM1 mutation status did not significantly affect induction CR rate. In our study of 869 pediatric AML patients, we showed an independent favorable outcome for the patients with NPM1 mutations in terms of 5-year EFS ($P = 0.001$) and OS ($P = 0.016$) compared to the patients with NPM1 wild-type. In addition, when focusing on the cytogenetically normal subgroup, NPM1 mutations also yielded better 5-year EFS ($P < 0.001$) and OS ($P < 0.001$) compared to NPM1 wild-type patients. However, when focusing on the cytogenetically abnormal subgroup, NPM1 mutations had no effect on EFS ($P = 0.159$) and OS ($P = 0.556$) (Fig. S3a, b). Furthermore, when excluding either an inv(16) or t(8; 21) in the cytogenetically abnormal subgroup, NPM1 mutations did not show favorable impact on EFS ($P = 0.411$) or OS ($P = 0.798$) in those patients (Fig. S3c, d). These findings were different from an adult cohort study, which showed that NPM1 mutations conferred favorable prognosis independently of whether cytogenetical status was normal or not.

It has been reported, in both adult and pediatric studies, that FLT3/ITD-mutated AML patients have poor prognoses. Furthermore, patients with a high AR of FLT3/ITD to wild-type alleles were reported to show poor
prognosis in pediatric AML.\textsuperscript{18,19} In our study, we found that FLT3/ITD mutations were significantly associated with poor EFS and OS. However, using an AR of 0.4, as described in a pediatric AML report,\textsuperscript{18} FLT3/ITD mutations yielded no significant differences in survival between high AR cases and low AR cases. Moreover, we did not find a negative influence on the outcome of FLT3/ITD mutations in the NPM1-mutated patients. Notably, within the FLT3/ITD-positive subgroup, NPM1-mutated patients had improved EFS and OS. NPM1 mutations confer an independent favorable impact in pediatric patients in spite of FLT3/ITD mutations. These findings were consistent with a pediatric study of Hollink et al.\textsuperscript{12} A large cohort of young adult patients with AML also reported that the beneficial impact of NPM1 mutations on survival was seen in FLT3/ITD-positive as well as FLT3 wild-type patients.\textsuperscript{20} Another adult study showed that effect of FLT3/ITD burden was modulated by NPM1 mutation, especially in patients with a low ratio.\textsuperscript{21} The differences between adult and pediatric studies are worthy of further investigation.

Next, we investigated the effect of SCT in pediatric patients with AML. We found that NPM1 mutations conferred favorable prognostic impact on survival in
Table 3  Multivariate analysis for EFS and OS in pediatric patients with AML.

| Outcome | Variable                      | Hazard ratio (95% CI) | P-value |
|---------|-------------------------------|-----------------------|---------|
| EFS     | NPM1                          | 0.473 (0.283–0.790)   | 0.004   |
|         | FLT3/ITD                      | 1.743 (1.296–2.345)   | <0.001  |
|         | SCT                           | 0.575 (0.419–0.790)   | 0.001   |
|         | Age >10                       | 1.098 (0.889–1.356)   | 0.387   |
|         | Abnormal cytogenetics          | 1.058 (0.789–1.420)   | 0.705   |
| OS      | NPM1                          | 0.452 (0.242–0.841)   | 0.012   |
|         | FLT3/ITD                      | 1.600 (1.132–2.263)   | 0.008   |
|         | SCT                           | 0.824 (0.580–1.171)   | 0.280   |
|         | Age >10                       | 1.192 (0.924–1.538)   | 0.176   |
|         | Abnormal cytogenetics          | 0.995 (0.707–1.401)   | 0.977   |

CI confidence interval, EFS event-free survival, FLT3/ITD internal tandem duplication of the FLT3 gene, OS overall survival, SCT stem cell transplantation

patients without SCT. SCT improved the EFS of patients with NPM1 wild-type and FLT3/ITD mutations. These findings are consistent with the concept that SCT is indicated for FLT3/ITD-positive AML patients without NPM1 mutations. However, our study revealed that SCT had no significant effect on the survival of patients with both NPM1 and FLT3/ITD mutations. Our results indicate that pediatric AML patients with both NPM1 and FLT3/ITD mutations had favorable prognoses and may not require hematopoietic stem cell transplantations. Multivariate analysis revealed that both NPM1 and FLT3/ITD mutations were highly significant independent predictors of outcome, while SCT was significantly associated with better EFS but not with better OS. The role of SCT in AML patients with both NPM1 and FLT3/ITD mutations remains controversial. According to the 2017 European LeukemiaNet recommendations, FLT3/ITD-negative AML patients with NPM1 mutations are not a priori assigned to allogeneic SCT in first CR. However, some studies indicated that allogeneic SCT improves the prognosis in NPM1-mutated AML with FLT3/ITD low AR. Recently, Huang et al. found that SCT have better survival in adult AML patients with both NPM1 and FLT3/ITD mutations comparing to chemotherapy alone.

The mechanism of NPM1 mutation in leukemogenesis remains unclear. Frameshift mutations in exon 12 of NPM1 are the most common mutation. All of the variants result in the insertion of four base pairs in the C-terminal region, causing loss of a nucleolar localization signal and aberrant localization of the protein to the cytoplasm. The types of NPM1 mutations are different between adult AML and pediatric AML. Type A mutation accounts for ~80% of all variants in adults but only accounts for 11.1–50% of all variants in pediatric AML. Hollink et al. found that no significant differences in outcome were detected between the different types of NPM1 mutations in pediatric AML. These findings were confirmed by some adult AML studies. However, Alperman et al. found that patients with the type-A mutation had less overall survival and worse event-free survival when compared to those harboring other NPM1 mutations. Moreover, their study showed that FLT3/ITD mutations in combination with the type-A mutation have much poorer prognosis when compared to FLT3/ITD mutations with type B and D cases. Recently, Patel et al. have reported that high variant allele frequency of NPM1 predict poor outcomes in de novo AML and the effect is not affected by FLT3/ITD. Murine model studies have showed that mutant NPM1 and FLT3/ITD exhibit a marked and potent molecular synergy toward driving AML pathogenesis. The mechanistic links between the various NPM1 mutations and FLT3/ITD reported in various clinical studies need to be further explored in molecular and murine model studies.

Taken together, we analyzed the impact of NPM1 mutations in 869 patients with AML, which is the largest pediatric AML cohort studied to date. Our findings showed that NPM1 mutations confer an independent favorable prognostic impact in pediatric AML, particularly in cytogenetically normal AML cases. Moreover, NPM1 mutations might be able to abrogate the negative prognostic influence of FLT3/ITD mutations. Pediatric patients with both NPM1 and FLT3/ITD mutations might have favorable prognoses, and those patients might not be requiring hematopoietic stem cell transplantation. Well-designed prospective studies are needed to evaluate the impact of hematopoietic stem cell transplantation in pediatric AML with co-occurring NPM1 and FLT3/ITD mutations.

Acknowledgements
This work was supported by the Natural Science Foundation of Guangdong Province, China (2018A030313680 to L.H. Xu), the Science and Technology Planning Project of Guangdong Province, China (2017A020215019 to L.H. Xu), the China Scholarship Council (201806385032 to L.H. Xu).

Author details
1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Pediatrics, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, People’s Republic of China. 2Department of Pathology, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA. 3Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang-Ming University, Taipei, Taiwan. 4Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA. 5Department of Biology, Davidson College, Davidson, NC 28035, USA.

Conflict of interest
The authors declare that they have no conflict of interest.
References

1. De Moerlooze, B. et al. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01. *Pediatr Blood Cancer* **66**, e27605 (2019).

2. Rubnitz, J. E. How I treat pediatric acute myeloid leukemia. *Blood* **119**, 5981–5988 (2012).

3. Kunzala, P., Kuravi, S., Jensen, R., McGuirk, J. & Balusu, R. When the good go bad: mutant NPM1 in acute myeloid leukemia. *Blood Rev* **32**, 167–183 (2018).

4. Heath, E. M. et al. Biological and clinical consequences of NPM1 mutations in AML. *Leukemia* **31**, 798–807 (2017).

5. Brunetti, L. et al. Mutant NPM1 maintains the leukemic state through HOX expression. *Cancer Cell* **34**, 499–512 (2018).

6. Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* **127**, 2391–2405 (2016).

7. Falini, B., Nicoletti, I., Martelli, M. F. & Mecucci, C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+) AML: biologic and clinical features. *Blood* **109**, 874–885 (2007).

8. Thiede, C. et al. Prevalence and prognostic impact of NPM1 mutation in 1485 adult patients with acute myeloid leukemia (AML). *Blood* **107**, 4011–4020 (2006).

9. Verhaak, R. G. et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. *Blood* **106**, 3747–3754 (2005).

10. Tsi, C. H. et al. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. *Leukemia* **30**, 1485–1492 (2016).

11. Brown, P. et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. *Blood* **110**, 979–985 (2007).

12. Hollink, I. H. et al. Favorable prognostic impact of NPM1 mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. *Leukemia* **23**, 262–270 (2009).

13. Cazzaniga, G. et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. *Blood* **110**, 1419–1422 (2005).

14. Eifeld, A. K. et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. *Leukemia* **32**, 1338–1346 (2018).

15. Haferlach, C. et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. *Blood* **114**, 3024–3032 (2009).

16. Daver, N., Schlenk, R. F., Russell, N. H. & Levis, M. J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. *Leukemia* **33**, 299–312 (2019).

17. Schnittger, S. et al. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. *Leukemia* **25**, 1297–1304 (2011).

18. Meshnich, S. et al. Clinical implications of FLT3 mutations in pediatric AML. *Blood* **108**, 3654–3661 (2006).

19. Shimada, A. et al. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. *Int. J. Hematol.* **107**, 586–595 (2018).

20. Gale, R. E. et al. The impact of FLT3 internal tandem duplication mutation level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. *Blood* **111**, 2776–2784 (2008).

21. Patraronna, M. et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. *Blood* **121**, 2734–2738 (2013).

22. Hasle, H. A critical review of which children with acute myeloid leukaemia need stem cell procedures. *Br. J. Haematol.* **166**, 23–33 (2014).

23. Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* **129**, 424–447 (2017).

24. Sakaguchi, M. et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia (AML). *Blood Adv.* **2**, 2744–2754 (2018).

25. Oran, B. et al. Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia. *Biol. Blood Marrow Transplant.* **22**, 1218–1226 (2016).

26. Huang, Y. et al. Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis. *Cancer Manag. Res.* **11**, 4129–4142 (2019).

27. Rau, R. & Brown, P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia towards definition of a new leukaemia entity. *Hematol Oncol. Sci.* **27**, 171–181 (2009).

28. Pastore, F. et al. The NPM1 mutation type has no impact on survival in cytogenetically normal AML. *PloS One* **9**, e109759 (2014).

29. Heidbig, M. et al. Impact of NPM1 mutation subtypes on treatment outcome in AML. The Lyon-University Hospital experience. *Leuk. Res.* **76**, 29–32 (2019).

30. Alpermann, T. et al. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. *Haematologica* **101**, e55–e58 (2016).

31. Patel, S. S. et al. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. *Blood* **131**, 2816–2825 (2018).

32. Patel, S. S. et al. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. *Am. J. Hematol.* **94**, 921–928 (2019).

33. Mupo, A. et al. A powerful molecular synergy between mutant Nucleophosmin and FLT3-ITD drives acute myeloid leukemia in mice. *Leukemia* **27**, 1917–1920 (2013).

34. Rau, R. et al. NPM1c+ cooperates with FLT3/ITD mutations to cause acute leukemia recapitulating human disease. *Exp. Hematol.* **42**, 101–113 (2014).